Page 25 - Discover Top Biotechnology Partners From Poland - Business Catalogue

Polish Biotechnology Sector Polish Biotechnology Sector

COMPANY NAME: Mabion S.A. COMPANY NAME: MEDICOFARMA BIOTECH S.A.

WEBSITE : https://www.mabion.eu/ WEBSITE : https://www.medicofarmabiotech.pl
YEAR OF ESTABLISHMENT: 2007 YEAR OF ESTABLISHMENT: 2021
NUMBER OF EMPLOYEES: 249 NUMBER OF EMPLOYEES: 23
CERTIFICATIONS: • GMP Certificate • GLP Certificate • ISO 14001:2015 • ISO CERTIFICATIONS: Good manufacturing practice (GMP)
45001:2018 • ISO 50001:2018
PRODUCTS: Mabion is a biologic CDMO providing multiple services related to PRODUCTS: Anticancer therapies based on RNA and low-molecular-weight
biologic drug development and manufacturing: • Clinical and compounds. Regenerative therapy based on low-molecular-weight
Commercial Manufacturing • Process Development • Pre-Clinical and compounds.
Clinical Analytics • Drug Characterization and Release Testing • Fill &
Finish • Regulatory and Consulting
FORM OF COOPERATION: CDMO Services FORM OF COOPERATION: Joint Venture, Investment

Mabion’s offer is directed to a wide spectrum of We deliver innovative therapies that address the unmet
biopharmaceutical companies seeking to outsource one clinical needs, especially patients suffering from severe
or more elements of their development program and/or cancer types, such as pancreatic cancer and glioblastoma
clinical or commercial manufacturing. Mabion was (GBM). Our leading project - “Anti-cancer therapy based on
established as an R&D company developing biosimilars, but RNA technology” is focused on GBM. Until now, we have
it has recently undergone a review of it’s in business developed and validated the efficacy and safety of three
strategy and became a focused end-to-end biologics therapeutic candidates in the preclinical proof-of-concept
CDMO. The company has well equiped GMP- and GLP- studies. The compounds and formulations are protected by
certified facilities with a dedicated platform for biologics three pending patents. The Company is preparing to initiate
manufacturing. Mabion has extensive experience in almost the first-in-human clinical trial. Designed therapy is a first
all facets of biologic medication research and production RNA-based alone or adjuvant therapy for the treatment of
thanks to the lenghty history of working on own products gliomas. We are a member of European Federation of
and contract manufacturing of COVID-19 vaccine antigens. Biotechnology.